Carbazole carboxamide compounds

US9714234B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Soo S. Ko · Hockessin, US
• Douglas G. Batt · Wilmington, US
• Myra Beaudoin Bertrand · Lambertville, US
• George V. DeLucca · Wilmington, US
• Charles M. Langevine · Brooklyn, US
• Qingjie Liu · Newtown, US
• Anurag S. Srivastava · Montgomery, US
• Scott Hunter Watterson · Pennington, US

Key dates

• Filing date: Jun 25, 2014
• Grant date: Jul 25, 2017
• Expiry date: Jun 25, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formula (I); and salts thereof, wherein: Formula (II); Q is: R1 is —C(CH3)2OH, —NHC(=0)C(CH3)3, —N(CH3)2, or —CH2Rd; R2 is CI or —CH3; R3 is H, F, or —CH3; Ra is H or —CH3; Rb is H, F, CI, or —OCH3 Rc is H or F; and Rd is —OH, —OCH3, —NHC(=0)CH3, or fORMULA (III), Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.